triazoles has been researched along with palbociclib in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 33 (94.29) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Fowst, C; Huang, X; Kim, ST; Kulyk, SO; Lang, I; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Shparyk, Y; Slamon, DJ; Thummala, AR; Voytko, NL | 1 |
| Dhillon, S | 1 |
| Henry, NL; Morikawa, A | 1 |
| Johnston, SR | 1 |
| Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Bell, T; Bhattacharyya, H; Crown, JP; Finn, RS; Huang Bartlett, C; Huang, X; Kim, S; Lang, I; Randolph, S; Slamon, D; Zanotti, G | 1 |
| Bromberg, DJ; Nanjappa, S; Pabbathi, S; Valenzuela, M | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Dedes, KJ; Klingbiel, D; Matter-Walstra, K; Ruhstaller, T; Schwenkglenks, M | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Bielski, CM; Boehm, JS; Cheah, JH; Church, AJ; Cima, MJ; Clemons, PA; Cowley, GS; Crompton, BD; Doshi, MB; Garraway, LA; Gill, S; Hahn, WC; Hong, AL; Howell, S; Imamovic, A; Janeway, KA; Jonas, O; Keskula, P; Kryukov, GV; Kynnap, BD; Langer, RS; Meyer, SC; Oh, C; Roberts, CW; Rodriguez-Galindo, C; Root, DE; Schreiber, SL; Shamji, AF; Stegmaier, K; Tseng, YY; Tsherniak, A; van Hummelen, P; Vazquez, F | 1 |
| Bartlett, CH; Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Huang, X; Kim, ST; Lang, I; Nadanaciva, S; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Schnell, P; Slamon, DJ | 1 |
| Niraula, S; Ocana, A | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Burki, TK | 1 |
| Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Harbeck, N; Im, SA; Jones, S; Lipatov, ON; Lu, DR; Martin, M; Moulder, S; Randolph, S; Rugo, HS; Slamon, DJ; Walshe, JM | 1 |
| Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A | 1 |
| Dedes, KJ; Matter-Walstra, K; Schwenkglenks, M | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Kim, ES; Scott, LJ | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Helou, J; Naimark, DM; Pritchard, KI; Raphael, J | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Freedman, RA; Tolaney, SM | 1 |
| Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Muramatsu, Y; Nagasawa, T; Nishimura, R; Ohno, S; Takahashi, M; Toi, M; Umeyama, Y | 1 |
| Durairaj, C; Ettl, J; Finn, RS; Gauthier, ER; Hoffman, JT; Huang, X; Joy, AA; Lu, DR; Rugo, HS; Ruiz-Garcia, A; Wang, DD; Wilner, KD; Zheng, J | 1 |
| Bolin, S; Borgenvik, A; Bradner, JE; Cho, YJ; Persson, CU; Qi, J; Sundström, A; Swartling, FJ; Weishaupt, H; Weiss, WA | 1 |
| Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
| Ding, D; Huang, H; Jimenez, R; Jin, X; Ma, T; Wang, D; Wang, L; Wu, H; Yan, Y; Ye, Z | 1 |
| Cichowski, K; Elledge, SJ; Liao, S; Maertens, O | 1 |
| Brown, M; Fassl, A; Ge, JY; Gulvady, A; Heavey, GA; Jovanović, B; Kuang, Y; Kwon, M; Luoma, A; McDonald, TO; Michor, F; Murphy, K; Paweletz, C; Pellman, D; Polyak, K; Qi, J; Shu, S; Sicinski, P; Thorner, AR; Trinh, A; Wucherpfennig, KW | 1 |
| Chen, Y; Deng, H; Du, W; Gao, H; He, Q; Lan, T; Li, T; Liu, Y; Meng, X; Rao, Y; Shao, X; Sun, X; Tao, X; Tong, Y; Wang, L; Wang, W; Wu, Y; Xu, A; Yang, B; Ying, M; Zhong, T | 1 |
11 review(s) available for triazoles and palbociclib
| Article | Year |
|---|---|
Palbociclib: first global approval.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Approval; Drug Interactions; Drugs, Investigational; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Triazoles; United States; United States Food and Drug Administration | 2015 |
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles | 2015 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
7 trial(s) available for triazoles and palbociclib
| Article | Year |
|---|---|
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; North America; Piperazines; Postmenopause; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Republic of Korea; South Africa; Time Factors; Treatment Outcome; Triazoles | 2015 |
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Pain; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Letrozole; Middle Aged; Nitriles; Pain Measurement; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neutropenia; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Survival Analysis; Treatment Outcome; Triazoles | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neutropenia; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Triazoles | 2016 |
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Piperazines; Postmenopause; Pyridines; Survival Analysis; Treatment Outcome; Triazoles | 2018 |
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Letrozole; Middle Aged; Nitriles; Piperazines; Pyridines; Triazoles | 2018 |
17 other study(ies) available for triazoles and palbociclib
| Article | Year |
|---|---|
Palbociclib ups PFS in HER2-/ER+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2014 |
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Drug Approval; Estrogen Receptor alpha; Female; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Metastasis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles | 2015 |
Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Hyperuricemia; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Triazoles | 2016 |
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Markov Chains; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Switzerland; Treatment Outcome; Triazoles | 2016 |
Integrated genetic and pharmacologic interrogation of rare cancers.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; CRISPR-Cas Systems; Cyclin-Dependent Kinase 4; Doxorubicin; Drug Screening Assays, Antitumor; Exome; Exportin 1 Protein; Female; Genomics; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Piperazines; Pyridines; Rare Diseases; Receptors, Cytoplasmic and Nuclear; RNA Interference; Sarcoma; Sequence Analysis, RNA; Triazoles | 2016 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Palbociclib improves survival in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2017 |
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Hepatectomy; Humans; Letrozole; Liver Neoplasms; Male; Markov Chains; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Survival Rate; Taxoids; Triazoles | 2017 |
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Receptors, Estrogen; Triazoles | 2017 |
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Medical Oncology; Nitriles; Piperazines; Pyridines; Triazoles | 2017 |
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug Costs; Female; Humans; Letrozole; Models, Economic; Nitriles; Ontario; Piperazines; Protein Kinase Inhibitors; Pyridines; Quality of Life; Stochastic Processes; Time Factors; Treatment Outcome; Triazoles | 2017 |
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Topics: Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Cyclin-Dependent Kinase 2; Drug Synergism; Female; Humans; Medulloblastoma; Piperazines; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Models, Biological; Models, Economic; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles; United States | 2018 |
DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Drug Resistance, Neoplasm; Endopeptidases; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Male; Mice; Nuclear Proteins; Nuclear Receptor Co-Repressor 2; Piperazines; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proteolysis; Pyridines; Signal Transduction; Transcription Factors; Transcription, Genetic; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclins; Drug Resistance, Neoplasm; E2F Transcription Factors; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Membrane Proteins; Mice; Mice, Nude; Monomeric GTP-Binding Proteins; Mutation; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Transcription Factors; Triazoles | 2018 |
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Checkpoints; Cell Proliferation; Clone Cells; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Mice; Models, Biological; Mutation; Paclitaxel; Piperazines; Ploidies; Proteins; Pyridines; Retinoblastoma Protein; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Discovery; Gene Expression Regulation, Leukemic; Humans; Ikaros Transcription Factor; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Myeloid Progenitor Cells; Piperazines; Primary Cell Culture; Proteolysis; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transcriptome; Triazoles | 2021 |